Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an early-stage trial, according to data published on Friday ahead of a healthcare conference next week.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on Friday.

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team